Amyotrophic Lateral Sclerosis (ALS) News and Research

RSS

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

An international study led by biologists and neuroscientists from the University of Pennsylvania has identified a new genetic risk factor for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease.

26 Aug 2010

Study finds genetic change in chromosome 4 causes FSHD

The Muscular Dystrophy Association today heralds a landmark muscular dystrophy advance by an international study team of scientists and physicians from the Netherlands, United States, France and Spain. Led by MDA-grantee Silvère van der Maarel, Ph.D., at Leiden University Medical Center in the Netherlands, the collaborative study of more than 2,300 people found that two distinct genetic changes on chromosome 4 must be present to cause facioscapulohumeral muscular dystrophy (FSHD).

21 Aug 2010

First pathological evidence of link between repeated head injuries and chronic traumatic Encephalomyopathy

Researchers with the Department of Veterans Affairs (VA) and the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine have provided the first pathological evidence of a link between repeated head injuries—such as those experienced by athletes in contact sports such as boxing, football, and hockey—and a disease (chronic traumatic Encephalomyopathy) that resembles amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

20 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

18 Aug 2010

Brain trauma in sports associated with motor neuron disease, researchers find

The Center for the Study of Traumatic Encephalopathy at Boston University School of Medicine and Department of Veterans Affairs announced today that they have provided the first pathological evidence that repetitive head trauma experienced in collision sports is associated with motor neuron disease, a neurological condition that affects voluntary muscle movements.

18 Aug 2010

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Professional athletes with repetitive head trauma and possibly others with a history of head injuries many years previously may be prone the development of a motor neuron disease similar to amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), reports a study in the September Journal of Neuropathology & Experimental Neurology, official journal of the American Association of Neuropathologists, Inc.

18 Aug 2010

NACTN receives grant to expand spinal cord injury research

The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.

18 Aug 2010

CVS/Pharmacy opens new store in Omaha

CVS/pharmacy celebrated its entry into the Omaha market today with a grand opening at one of its two new stores in the city of Omaha. Joining CVS officials at the ceremony were The Honorable Jim Suttle, Mayor of Omaha and City Councilmember Thomas Mulligan, District #7.

16 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Study finds lithium drugs not effective for amyotrophic lateral sclerosis treatment

A new study has found that the drug lithium is not effective in treating people with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. The research is published in the August 11, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Aug 2010

Common soluble proteins become insoluble and form aggregates while aging: Study

In neurodegenerative diseases, clumps of insoluble proteins appear in patients' brains. These aggregates contain proteins that are unique to each disease, such as amyloid beta in Alzheimer's disease, but they are intertwined with small amounts of many other insoluble proteins that are normally present in a soluble form in healthy young individuals. For years, these other proteins were thought to be accidental inclusions in the aggregates, much as a sea turtle might be caught in a net of fish.Now, in a surprising new finding, researchers at the University of California, San Francisco, report that many of the proteins present as minor components of disease aggregates actually clump together as a normal part of aging in healthy individuals.

11 Aug 2010

Insmed second-quarter net loss decreases to $0.4 million

Insmed Inc., a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2010.

4 Aug 2010

Researchers discover potential method for neurodegenerative disease detection

New investigations, initiated by research workers at CIC bioGUNE and led by Dr. Aitor Hierro, have opened possibilities for making progress in the knowledge and prediction of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), according to the journal of The Proceedings of the National Academy of Sciences of the United States of America.This study opens the possibility of research in humans to detect this pathology before the symptoms arise.

26 Jul 2010

New research focuses on calcium channels in lysosome membrane

In cells, as in cities, disposing of garbage and recycling anything that can be reused is an essential service. In both city and cell, health problems can arise when the process breaks down.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Research findings suggest possible diagnostic test for ALS

A team led by a Los Angeles Biomedical Research Institute researcher developed a novel approach to efficiently identify disease relevant genes in human complex neurological disorders and demonstrated the effectiveness of this method by applying it to Amyotrophic Lateral Sclerosis, or Lou Gehrig's Disease, according to a new study reported online in the journal, Human Molecular Genetics.

25 Jun 2010

Amyotrophic Lateral Sclerosis (ALS) News and Research

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

Study finds genetic change in chromosome 4 causes FSHD

First pathological evidence of link between repeated head injuries and chronic traumatic Encephalomyopathy

Muscular Dystrophy Association awards $14.1M in new grants

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Brain trauma in sports associated with motor neuron disease, researchers find

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

NACTN receives grant to expand spinal cord injury research

CVS/Pharmacy opens new store in Omaha

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Study finds lithium drugs not effective for amyotrophic lateral sclerosis treatment

Common soluble proteins become insoluble and form aggregates while aging: Study

Insmed second-quarter net loss decreases to $0.4 million

Researchers discover potential method for neurodegenerative disease detection

New research focuses on calcium channels in lysosome membrane

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Neuralstem announces completion of $10 million registered direct offering

Research findings suggest possible diagnostic test for ALS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News